Literature DB >> 7604013

Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.

D R Duan1, J S Humphrey, D Y Chen, Y Weng, J Sukegawa, S Lee, J R Gnarra, W M Linehan, R D Klausner.   

Abstract

The human VHL tumor suppressor gene has been implicated in the inherited disorder von Hippel-Lindau disease and in sporadic renal carcinoma. The homologous rat gene encodes a 185-amino acid protein that is 88% sequence identical to the aligned 213-amino acid human VHL gene product. When expressed in COS-7 cells, both the human and the rat VHL proteins showed predominant nuclear, nuclear and cytosolic, or predominant cytosolic VHL staining by immunofluorescence. A complicated pattern of cellular proteins was seen that could be specifically coimmunoprecipitated with the introduced VHL protein. A complex containing VHL and proteins of apparent molecular masses 16 and 9 kDa was the most consistently observed. Certain naturally occurring VHL missense mutations demonstrated either complete or partial loss of the p16-p9 complex. Thus, the VHL tumor suppressor gene product is a nuclear protein, perhaps capable of specifically translocating between the nucleus and the cytosol. It is likely that VHL executes its functions via formation of specific multiprotein complexes. Identification of these VHL-associated proteins will likely clarify the physiology of this tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7604013      PMCID: PMC41537          DOI: 10.1073/pnas.92.14.6459

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.

Authors:  Y Takebe; M Seiki; J Fujisawa; P Hoy; K Yokota; K Arai; M Yoshida; N Arai
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

2.  A nuclear pore complex protein that contains zinc finger motifs, binds DNA, and faces the nucleoplasm.

Authors:  J Sukegawa; G Blobel
Journal:  Cell       Date:  1993-01-15       Impact factor: 41.582

Review 3.  Tumor suppressor genes.

Authors:  P W Hinds; R A Weinberg
Journal:  Curr Opin Genet Dev       Date:  1994-02       Impact factor: 5.578

4.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.

Authors:  T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

5.  Identification of the von Hippel-Lindau disease tumor suppressor gene.

Authors:  F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

6.  Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene.

Authors:  J Gao; J G Naglich; J Laidlaw; J M Whaley; B R Seizinger; N Kley
Journal:  Cancer Res       Date:  1995-02-15       Impact factor: 12.701

7.  Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.

Authors:  F Chen; T Kishida; M Yao; T Hustad; D Glavac; M Dean; J R Gnarra; M L Orcutt; F M Duh; G Glenn
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

8.  Mutations of the VHL tumour suppressor gene in renal carcinoma.

Authors:  J R Gnarra; K Tory; Y Weng; L Schmidt; M H Wei; H Li; F Latif; S Liu; F Chen; F M Duh
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

9.  Localization of TGN38 to the trans-Golgi network: involvement of a cytoplasmic tyrosine-containing sequence.

Authors:  J S Humphrey; P J Peters; L C Yuan; J S Bonifacino
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

10.  Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport.

Authors:  J Pines; T Hunter
Journal:  J Cell Biol       Date:  1991-10       Impact factor: 10.539

View more
  33 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.

Authors:  R Rajasekaran; C Sudandiradoss; C George Priya Doss; Anshuman Singh; Rao Sethumadhavan
Journal:  Mamm Genome       Date:  2008-10-03       Impact factor: 2.957

3.  Neurologic manifestations of von Hippel-Lindau disease.

Authors:  John A Butman; W Marston Linehan; Russell R Lonser
Journal:  JAMA       Date:  2008-09-17       Impact factor: 56.272

4.  Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.

Authors:  S Lee; M Neumann; R Stearman; R Stauber; A Pause; G N Pavlakis; R D Klausner
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families.

Authors:  T Kamura; S Sato; D Haque; L Liu; W G Kaelin; R C Conaway; J W Conaway
Journal:  Genes Dev       Date:  1998-12-15       Impact factor: 11.361

6.  VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling.

Authors:  E J Davidowitz; A R Schoenfeld; R D Burk
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

Review 7.  Pancreatic lesions in von Hippel-Lindau disease? A systematic review and meta-synthesis of the literature.

Authors:  Michael Charlesworth; Caroline S Verbeke; Gavin A Falk; Matthew Walsh; Andrew M Smith; Gareth Morris-Stiff
Journal:  J Gastrointest Surg       Date:  2012-02-28       Impact factor: 3.452

8.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

9.  Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.

Authors:  Isabelle Groulx; Stephen Lee
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

10.  Phosphorylation-dependent cleavage regulates von Hippel Lindau proteostasis and function.

Authors:  P German; S Bai; X-D Liu; M Sun; L Zhou; S Kalra; X Zhang; R Minelli; K L Scott; G B Mills; E Jonasch; Z Ding
Journal:  Oncogene       Date:  2016-03-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.